Literature DB >> 15338749

Mucins in gastrointestinal cancers.

Michael S Turner1, John R McKolanis, Ramesh K Ramanathan, David C Whitcomb, Olivera J Finn.   

Abstract

The mucin family has been under study by molecular biologists, biochemists, pathologists and immunologists interested in cancer because of the role these molecules can play in the diagnosis and treatment of cancer. Immense knowledge has been accumulated, but the high speed of progress in the laboratory has not been matched by the progress towards applying this knowledge in the clinic. For example, specific knowledge of cancer-associated changes in the expression and glycosylation of various mucins, which can aid in the diagnosis as well as prognosis of GI cancers, has not yet led to the use of a panel of anti-mucin antibodies as a standard diagnostic tool. Similarly, many more opportunities exist for using mucin-based therapies than are currently being considered in the clinic. This chapter aimed to highlight some of these opportunities and to interest clinician scientists in exploring them in the near future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15338749     DOI: 10.1016/s0921-4410(03)21012-7

Source DB:  PubMed          Journal:  Cancer Chemother Biol Response Modif        ISSN: 0921-4410


  3 in total

1.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

2.  Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma.

Authors:  Karina Galoian; Silva Abrahamyan; Gor Chailyan; Amir Qureshi; Parthik Patel; Gil Metser; Alexandra Moran; Inesa Sahakyan; Narine Tumasyan; Albert Lee; Tigran Davtyan; Samvel Chailyan; Armen Galoyan
Journal:  Int J Oncol       Date:  2017-11-09       Impact factor: 5.650

3.  Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential.

Authors:  Jason J Lohmueller; Shuji Sato; Lana Popova; Isabel M Chu; Meghan A Tucker; Roberto Barberena; Gregory M Innocenti; Mare Cudic; James D Ham; Wan Cheung Cheung; Roberto D Polakiewicz; Olivera J Finn
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.